Exploring the therapeutic potential of IL-17A inhibition in myasthenia gravis: a retrospective study on secukinumab.

ABSTRACT:

Abstract

Objective

Targeting interleukin-17A (IL-17A) represents a potential therapeutic strategy for myasthenia gravis (MG), but its clinical effects and immunomodulatory mechanisms remain incompletely defined. This study investigated the multidimensional efficacy and immune kinetic profile of secukinumab (SEC) in patients with MG.

Methods

We retrospectively enrolled acetylcholine receptor (AChR) antibody-positive (AChR-Ab⁺) generalised patients with MG (MG Foundation of America class IIa-IVb) treated at the Department of Neurology, Peking University People's Hospital between February 2023 and November 2024. All patients received SEC therapy (150 mg weekly for 4 weeks, followed by 150 mg every 4 weeks as maintenance for 24 weeks). Stable doses of conventi

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC12606481 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature